Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. develops novel immunotherapies for cancer, with a company focus on metastatic and advanced breast cancer. Its recurring news centers on Bria-IMT™, the lead cell-based immunotherapy evaluated with an immune checkpoint inhibitor in the Bria-ABC study, and on the Bria-OTS™ and Bria-OTS+™ personalized off-the-shelf immunotherapy platforms.
Company updates also cover FDA clearance activity for Bria-BRES+™, additions of clinical trial sites, presentations at oncology meetings such as ASCO, AACR and SABCS, and biomarker, survival, quality-of-life and tolerability data from breast cancer studies. BriaCell news frequently ties its clinical programs to metastatic breast cancer populations with limited prior treatment options.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) presented promising clinical data from its Bria-IMT™ regimen at the 2023 American Association for Cancer Research Annual Meeting. Of the 18 patients studied since 2021, 15 remain alive, showcasing a significant survival benefit compared to typical outcomes in similar cohorts. The treatment demonstrated effective immune system activation, especially in patients with advanced metastatic breast cancer who had failed prior therapies. The data indicates improved progression-free survival (PFS) rates and a tolerable safety profile. BriaCell is also advancing Bria-OTS2.0, an enhanced version of its personalized immunotherapy, which shows potential for greater clinical efficacy. The ongoing studies aim to further validate these findings and address the unmet needs in metastatic breast cancer treatment.